il2rg gene into the blood forming stem cells (cd34+ cells)
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03601286)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LymphocytesSupplementation
supplementation - lymphocytes
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05207657 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2022 | University of London |
| NCT03601286 | Phase 1 | Oct 31, 2018 | University of London |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of London | Academic/Hospital | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1